To further assess the clinical response of heterogeneous CAF subsets to neoadjuvant anti-PD1 combination therapy in ESCC, we conducted a comprehensive UMAP analysis and compared CAF subclusters in treatment-naïve and treated samples (Fig. 4A). This evidence concerns the gene PDCD1 and esophageal squamous cell carcinoma.